In the Media - Starpharma

Nanotechnology Offers New Ways To Fight An Endless Pandemic

Oct 18th, 2021

Starpharma's VIRALEZE™ antiviral nasal spray was featured in Report Wire.

Nanotechnology offers alternative ways to fight COVID-19 pandemic with antivirals

Oct 14th, 2021

Starpharma's VIRALEZE™ antiviral nasal spray was featured in the October issue (VOL 39) of Nature Biotechnology.

Starpharma (ASX:SPL) shows 99.99pc antiviral activity against Delta COVID-19 variant

Jul 27th, 2021

"Starpharma's (SPL) SPL7013 drug has shown a reduction of more than 99.99 per cent against the Delta variant of SARS-CoV-2," The Market Herald reports. Read the full article here. Read More

COVID-19: Viraleze Nasal Spray Highly Effective Against Alpha, Beta And Gamma Variants

Jun 19th, 2021

"New data released on June 18 showed that Australia’s Viraleze anti-COVID nasal spray is more than 99.99 per cent effective against three of the four variants of the SARS-CoV-2 virus," as reported by Republic World. Read the full article here.

Latest Testing Confirms Viraleze Highly Effective Against Alpha, Beta and Gamma COVID Variants

Jun 18th, 2021

News18 reports on Starpharma's latest VIRALEZETM announcement: "New data released today shows that Australia’s Viraleze anti-COVID nasal spray is more than 99.9% effective against three of the four deadliest variants of the SARS-CoV-2 virus." Read the full article here.

Latest testing confirms Viraleze highly effective against Alpha, Beta and Gamma COVID variants

Jun 18th, 2021

Markets Insider features Starpharma's latest announcement, ..."The results hold significant promise for Viraleze™ – developed by Melbourne-based biopharmaceutical company Starpharma (ASX: SPL) – in the fight against new and emerging variants of SARS-CoV-2, as several countries begin their long-awaited opening of international borders..." Read the full article here.

Latest testing confirms Viraleze highly effective against Alpha, Beta and Gamma COVID variants

Jun 18th, 2021

"New data released today shows that Australia's Viraleze™ anti-COVID nasal spray is more than 99.9% effective against three of the four deadliest variants of the SARS-CoV-2 virus," as reported by the New Delhi Times. Read the full article here.

Starpharma (ASX:SPL) shows 99.9pc antiviral activity against three COVID-19 variants

Jun 18th, 2021

"Starpharma's (SPL) SPL7013 drug has shown a reduction of more than 99.9 per cent against the Alpha, Beta and Gamma SARS-CoV-2 variants," The Market Herald reports. Read the full article here.

Scripps Research Institute testing shows Viraleze highly active against UK COVID strain

Jun 1st, 2021

Markets Insider featured Viraleze and Starpharma following the announcement of SPL7013's potent antiviral activity against the UK coronavirus variant. Read the full article here.

Starpharma (ASX:SPL)'s nasal spray achieves 98% efficacy against COVID-19

Jun 1st, 2021

"Biopharmaceutical company Starpharma (ASX:SPL) claims the company’s nasal spray product is a highly efficacious means of protection from the UK variant of the coronavirus," Finance News Network reports. Read the full article here.

Starpharma (ASX:SPL) shows 98pc antiviral activity against U.K COVID-19 variant

Jun 1st, 2021

The Market Herald reports on Starpharma's latest announcement: "Starpharma (SPL) has confirmed that its SPL7013 drug has potent antiviral activity against the U.K. SARS-CoV-2 variant.

"In laboratory studies, SPL7013 achieved a reduction of more than 98 per cent against the virus."

Read the full article here.

Tackling Covid: How the Harlequins are defending themselves

May 22nd, 2021

Twickenham Nub News interviewed Harlequins’ Head of Medical Services, Mike Lancaster, about the partnership with Viraleze. "The Harlequins’ long-awaited return to Twickenham Stoop has seen the team make many changes to ensure players’ safety.

"Alongside several changes at the stadium, the team has also started defending itself with a new nose spray, Viraleze." Read the full article here.

Tax incentives to encourage innovation

May 18th, 2021

Dr Jackie Fairley, CEO of Starpharma discusses the Australian governments proposals for a 'patent box' and what it will mean for the company and Australian innovation in general. Watch here. (ausbiz account required)

Harlequins Partners with Anti-Viral Nasal Spray Viraleze

May 11th, 2021

Sport Industry Group featured the announcement of Starpharma's VIRALEZE^TM partnership with Harlequins. "Harlequins has announced a new partnership with antiviral nasal spray VIRALEZE^TM, which the club says it will use as one part of its suite of measures put in place to help protect its players and coaching staff." Read more here.

Harlequins Partners Antiviral Nasal Spray Brand Viraleze

May 11th, 2021

iSportconnect reported on the new partnership between Starpharma's antiviral nasal spray, VIRALEZE^TM, and Harlequins, a professional rugby union team in the UK. Read more here.

Starpharma (ASX:SPL) launches antiviral nasal spray in Europe

May 6th, 2021

The Market Herald reported on Starpharma's launch of VIRALEZE™ in Europe. Read the full article here.

Starpharma’s (SPL) antiviral nasal spray is now available for purchase by consumers in Europe via the company’s online store
VIRALEZE is a broad spectrum antiviral nasal spray, which studies have shown can inactivate more than 99.9 per cent of coronavirus pathogens within one minute
The product is already available online in the U.K. and through Lloyds Pharmacy’s 1400 stores, with the company now pursuing avenues to provide rapid access for VIRALEZE in India
Starpharma shares are up 3.93 per cent, trading at $1.85

Australian company develops a $27 anti-viral nasal spray that 'deactivates' Covid - and it's being used right across the UK

May 4th, 2021

Eliza McPhee for Daily Mail Australia reported: An Australian biotech company has joined the fight against coronavirus by launching an anti-viral nasal spray that's already available in the UK. Read the article here.

Biotech company Starpharma has launched anti-viral nasal spray in the UK
It acts as a barrier to coronavirus, trapping it in the nose and inactivating virus
Spray best used once every six hours for up to 30 days, CEO Jackie Fairley says
Melbourne-based company says it has plans to launch product soon in Australia

Starpharma (ASX:SPL) spends March quarter developing VIRALEZE

Apr 28th, 2021

Starpharma featured in The Market Herald following the announcement of Starpharma's Quarterly Cashflow and Activities Report. Read more here.

GlaxoSmithKline hoping to deliver Australia’s next COVID treatment

Apr 16th, 2021

Starpharma featured in The Sydney Morning Herald's daily COVID-19 update, as reported by Emma Koehn: ASX-listed companies have pivoted swiftly towards virus treatments and preventative in the past year, including Melbourne-based Starpharma which successfully brought a nasal spray to market in the UK last month. Read more here.

Aussie virus killer not to be sneezed at

Apr 11th, 2021

The Australian interviewed Dr Jackie Fairley, Starpharma CEO, about the recent launch of Viraleze in the UK. "As the nation hyperventilates over a delay in the vaccine rollout, Starpharma is rolling out a new line of defence against the coronavirus in global markets." Read more here. (Behind paywall)